PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2026 | $1,720,000 | Replaced |
| 4th Quarter - Amendment (this page) | Mar 12, 2026 | $1,780,000 | Replaced |
| 4th Quarter - Amendment | Aug 3, 2026 | $1,790,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANCISCO CARRILLO | — |
| EMILY MUELLER | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Medicare/Medicaid MMM
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANCISCO CARRILLO | — |
| EMILY MUELLER | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Trade (domestic/foreign) TRD
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELISSA ALBEN | — |
| FRANCISCO CARRILLO | — |
| STEPHEN CLAEYS | — |
| EMILY MUELLER | — |
| CATHERINE ROBINSON | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.